Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.50 USD
+0.07 (4.90%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.50 0.00 (0.00%) 4:30 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
MRNS 1.50 +0.07(4.90%)
Will MRNS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRNS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRNS
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
MRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Posts New Data From Bone Disease Study
SAGE's Huntington's Disease Study Meets Primary Endpoint
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
Other News for MRNS
Class Action Lawsuit against Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
Marinus Pharmaceuticals announces China NMPA approval for ganaxolone
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action – Contact Levi & Korsinsky LLP to Learn More
Hold Rating on Marinus’s IV Ganaxolone Amid Regulatory and Commercial Uncertainty